Johnson & Johnson lowered its 2026 adjusted profit forecast to a range of $10.96 to $11.11 per share. This revision marks a decrease from the previous guidance of $11.60 to $11.75 per share.
The updated outlook accounts for the $1 billion cash acquisition of oncology firm Firefly Bio. The company also finalized a partnership with Sail Biomedicines focused on autoimmune disease therapies.
These strategic deals will result in research and development charges that reduce adjusted earnings by approximately $0.64 per share. Johnson & Johnson maintained its existing full-year revenue forecast.